Infections associated with steroid use.

State University of New York School of Medicine, Stony Brook, New York, USA.
Infectious Disease Clinics of North America (Impact Factor: 2.31). 07/2001; 15(2):423-32, viii. DOI: 10.1016/S0891-5520(05)70154-9
Source: PubMed

ABSTRACT Patients receiving chronic steroids have an increased susceptibility to many different types of infections. The risk of infection is related to the dose of steroid and the duration of therapy. Although pyogenic bacteria are the most common pathogens, chronic steroid use increases the risk of infection with intracellular pathogens such as Listeria, many fungi, the herpes viruses, and certain parasites. Clinicians should consider both common and unusual opportunistic infections in patients receiving chronic steroids.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Context: Incidental benign adrenocortical adenomas, 'adrenal incidentalomas', are found in 4.5% of abdominal CT scans, with the incidence increasing to 10% in patients over 70 years. These incidentalomas frequently show evidence of excess cortisol secretion but without overt Cushing's syndrome. The mortality rate is increased in Cushing's syndrome. Objective: To investigate whether patients with adrenal incidentalomas have an increased mortality. Design : A retrospective, longitudinal cohort study. Setting: Endocrine Investigation Unit in a University Teaching Hospital. Patients : Two hundred and seventy two consecutive patients with an incidental adrenal mass underwent a dedicated diagnostic protocol, which included dexamethasone testing for hypercortisolism between 2005 and 2013. Overall survival was assessed in 206 patients with a benign, adrenocortical adenoma. Main Outcome Measures: Survival analysis was carried out by using Kaplan-Meier curves and the impact of dexamethasone cortisol estimated by Cox-regression analysis. Cause-specific mortality was ascertained from death certificates and compared to local and national data. Results: 18/206 patients died and the mean time (SD) from diagnosis to death was 3.2 (1.7) years. 17/18 patients who died had a post dexamethasone cortisol >1.8μg/dL and there was a significant decrease in survival rate with increasing dexamethasone cortisol levels (p=0.001). Compared with the <1.8μg/dL group, the hazard ratio (95%CI) for the 1.8 - 5μg/dL group was 12.0 (1.6 - 92.6) whilst that of the >5μg/dL group was 22.0 (2.6 - 188.3). 50% and 33% of deaths were secondary to circulatory or respiratory/infective causes, respectively. Conclusion: Patients with adrenal incidentalomas and a post-dexamethasone serum cortisol >1.8μg/dL have increased mortality, mainly related to cardiovascular disease and infection.
    The Journal of Clinical Endocrinology and Metabolism 09/2014; · 6.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The association between hyperglycemia and infections during induction chemotherapy has been reported in a number of hematologic disorders. This retrospective study evaluated the incidence of hyperglycemia during induction therapy in 155 patients with newly diagnosed multiple myeloma (MM) and its effect on serious infections during the first 60 days of induction. A total of 20 (12.9%) patients developed overt hyperglycemia (≥200 mg/dL) during induction therapy. Serious infections occurred in 28 (18.1%) of 155 patients and infection-related mortality within 2 months after treatment was 0.6% (1 patient). In a univariate analysis, overt hyperglycemia, poor performance status (≥2), International Staging System III, lymphopenia (<500/ μ L), and elevated serum creatinine (≥2 mg/dL) were found to be associated with serious infections. In multivariate analysis, only overt hyperglycemia (HR 7.846, 95% CI 2.512-24.503, P < 0.001) and poor performance status (HR 5.801, 95% CI 1.974-17.050, P = 0.001) remained significant. In conclusion, this study demonstrated an association between hyperglycemia and serious infections during induction therapy in patients with MM.
    BioMed research international. 01/2014; 2014:413149.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Plasma cell myeloma (PCM) is increasing in prevalence in older age groups and infective complications are a leading cause of mortality. Patients with PCM are at increased risk of severe infections, having deficits in many arms of the immune system due to disease and treatment-related factors. Treatment of PCM has evolved over time with significant impacts on immune function resulting in changing rates and pattern of infection. Recently, there has been a paradigm shift in the treatment of PCM with the use of immunomodulatory drugs and proteasome inhibitors becoming the standard of care. These drugs have wide-ranging effects on the immune system but their impact on infection risk and aetiology remain unclear. The aims of this review are to discuss the impact of patient, disease and treatment factors on immune function over time for patients with PCM and to correlate immune deficits with the incidence and aetiology of infections seen clinically in patients with PCM. Preventative measures and the need for clinically relevant tools to enable infective profiling of patients with PCM are discussed.
    Blood reviews 03/2014; · 7.19 Impact Factor


Available from